303 related articles for article (PubMed ID: 24898537)
1. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
[TBL] [Abstract][Full Text] [Related]
2. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
[TBL] [Abstract][Full Text] [Related]
3. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
4. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
Williams DS; McCracken PJ; Purcell M; Pickarski M; Mathers PD; Savitz AT; Szumiloski J; Jayakar RY; Somayajula S; Krause S; Brown K; Winkelmann CT; Scott BB; Cook L; Motzel SL; Hargreaves R; Evelhoch JL; Cabal A; Dardzinski BJ; Hangartner TN; Duong LT
Bone; 2013 Oct; 56(2):489-96. PubMed ID: 23806798
[TBL] [Abstract][Full Text] [Related]
5. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
Genant HK; Libanati C; Engelke K; Zanchetta JR; Høiseth A; Yuen CK; Stonkus S; Bolognese MA; Franek E; Fuerst T; Radcliffe HS; McClung MR
Bone; 2013 Oct; 56(2):482-8. PubMed ID: 23871852
[TBL] [Abstract][Full Text] [Related]
6. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
[TBL] [Abstract][Full Text] [Related]
7. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
[TBL] [Abstract][Full Text] [Related]
8. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
Rizzoli R; Benhamou CL; Halse J; Miller PD; Reid IR; Rodríguez Portales JA; DaSilva C; Kroon R; Verbruggen N; Leung AT; Gurner D
Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional structural analysis of the proximal femur in an age-stratified sample of women.
Nicks KM; Amin S; Melton LJ; Atkinson EJ; McCready LK; Riggs BL; Engelke K; Khosla S
Bone; 2013 Jul; 55(1):179-88. PubMed ID: 23486182
[TBL] [Abstract][Full Text] [Related]
10. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
[TBL] [Abstract][Full Text] [Related]
11. Inverse Correlation at the Hip Between Areal Bone Mineral Density Measured by Dual-Energy X-ray Absorptiometry and Cortical Volumetric Bone Mineral Density Measured by Quantitative Computed Tomography.
Amstrup AK; Jakobsen NF; Lomholt S; Sikjaer T; Mosekilde L; Rejnmark L
J Clin Densitom; 2016; 19(2):226-33. PubMed ID: 25700661
[TBL] [Abstract][Full Text] [Related]
12. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density averaged over a region of interest on femur is affected by age-related change of bone geometry.
Luo Y
Osteoporos Int; 2018 Jun; 29(6):1419-1425. PubMed ID: 29508039
[TBL] [Abstract][Full Text] [Related]
14. Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study.
Yang L; Udall WJ; McCloskey EV; Eastell R
Osteoporos Int; 2014 Jan; 25(1):251-63. PubMed ID: 23719860
[TBL] [Abstract][Full Text] [Related]
15. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
16. Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial.
Amstrup AK; Sikjaer T; Heickendorff L; Mosekilde L; Rejnmark L
J Pineal Res; 2015 Sep; 59(2):221-9. PubMed ID: 26036434
[TBL] [Abstract][Full Text] [Related]
17. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
18. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
[TBL] [Abstract][Full Text] [Related]
19. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
McClung MR; Zanchetta JR; Høiseth A; Kendler DL; Yuen CK; Brown JP; Stonkus S; Goemaere S; Recknor C; Woodson GC; Bolognese MA; Franek E; Brandi ML; Wang A; Libanati C
J Clin Densitom; 2013; 16(2):250-6. PubMed ID: 22572531
[TBL] [Abstract][Full Text] [Related]
20. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
Engelke K; Nagase S; Fuerst T; Small M; Kuwayama T; Deacon S; Eastell R; Genant HK
J Bone Miner Res; 2014 Mar; 29(3):629-38. PubMed ID: 24038152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
